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Abstract 
Background: Colorectal cancer (CRC) is the third leading cause of cancer mortality worldwide and is associated with 
high recurrence and mortality, despite recent advancements in therapeutic strategies. MicroRNA (miR) deregulation 
is associated with CRC development and recurrence; therefore, miRs may be reliable biomarkers for detecting early 
relapse postoperatively.
Methods: In this study ten candidates were identified using miR arrays: miR‑7, miR‑31, miR‑93, miR‑141, miR‑195, 
miR‑375, miR‑429, miR‑494, miR‑650, and let‑7b. Substantial differences were observed in their expression levels 
between early relapsed (recurrences within 12 months after surgery) and non‑early relapsed CRC patients. The valida‑
tion study, including 50 early relapsed and 54 non‑early relapsed patients, confirmed miR expression alterations in 
cancer tissue samples.
Results: Using a miR real‑time quantitative polymerase chain reaction (RT‑qPCR), we observed that expression levels 
of miR‑93, miR‑195, and let‑7b were significantly decreased, whereas those of miR‑7, miR‑141 and miR‑494 showed 
increases that were more significant in the CRC tissue samples from the early relapsed patients than in those from 
the non‑early relapsed patients. Disease‑free survival and overall survival were significantly worse in the high miR‑7, 
miR‑141, and miR‑494 expression subgroups and the low miR‑93 and miR‑195 expression subgroups (all P < 0.05). A 
panel of 6 miRs (miR‑7, miR‑93, miR‑195, miR‑141, miR‑494, and let‑7b), at a cut‑off value of 2 deregulated miRs, dis‑
tinguished early relapsed CRC from non‑early relapsed CRC, with a sensitivity of 76.6 % and a specificity of 71.4 %. By 
combining this 6‑miRs panel with 6 clinicopathologic factors, at a cut‑off value of 4, distinguished early relapsed CRC 
from non‑early relapsed CRC, with a sensitivity of 89.4 % and a specificity of 88.9 %.
Conclusions: This study showed that the developed miR panel has the potential to improve predicting early relapse 
in CRC patients.
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Background
Colorectal cancer (CRC) is the third leading cause of can-
cer mortality worldwide and accounts for approximately 
608,000 deaths worldwide [1, 2]. Although consider-
able improvement in radical resection has ensured highly 
effective treatment of localized diseases, recurrence/
metastasis is observed in 25–40  % of patients, leading 
to death within 5 years of diagnosis [3, 4]. Furthermore, 
patients’ recurrence period correlates strongly with the 
patients’ survival period [5]. A reliable biomarker for the 




*Correspondence:  cy614112@ms14.hinet.net; jayuwa@cc.kmu.edu.tw 
7 Division of Colorectal Surgery, Department of Surgery, Kaohsiung 
Medical University Hospital, Kaohsiung Medical University, No. 100 Tzyou 
First Road, Kaohsiung 807, Taiwan
Full list of author information is available at the end of the article
Page 2 of 12Yang et al. J Transl Med  (2016) 14:108 
in conducting treatments that are more aggressive and 
would be beneficial to patients [6, 7]. In our previous 
researches, we had mentioned the relevant clinicopatho-
logical factors which related the early relapse: (1) surgi-
cal in resected stage II colorectal cancer is dependent 
on tumor depth, vascular invasion, postoperative CEA 
level, and the number of examined lymph node [8]; (2) 
predictive value of vascular endothelial growth fac-
tor overexpression in early relapse of colorectal cancer 
patients after curative resection [9]; (3) S100B protein 
expression as an independent predictor of early relapse in 
UICC stage II and III colon cancer patients after curative 
resection [10] and (4) predictive factors of early relapse 
in UICC stage I-III colorectal cancer patients after cura-
tive resection [11]. Currently, investigators are searching 
extensively for the ideal biomarker or indicator for pre-
dicting clinical outcomes of CRC patients [7, 12, 13].
CRC tumorigenesis and metastasis involve multistep 
genomic changes, including the activation of oncogenes, 
inactivation of tumor suppressor genes, and increases in 
the ability of cell migration, tissue invasion, and organ 
colonization [14, 15]. A mature microRNA (miR) is a 
noncoding small RNA that can regulate the expression of 
downstream target genes posttranscriptionally [16]. The 
dysregulation of miRs can be either upregulated or down-
regulated in cancers and has therefore been suggested to 
play roles in the carcinogenesis, progression, and metas-
tasis of cancers [6, 16–19]. Consequently, miRs have the 
potential to serve as biomarkers for cancer detection and 
prognostic prediction [6, 12, 20].
Although several reports and reviews have suggested 
that deregulated miRs are involved in the pathogenesis of 
CRC [17, 21–25], few studies have focused on the associ-
ation between miRs and the early relapse of CRC. A miR 
array assay was applied to compare miR profiles between 
CRC tissue samples (test cohort) from early and non-
early relapsed patients. We identified 10 candidates, miR-
7, miR-31, mi-93, miR-141, miR-195, miR-375, miR-429, 
miR-494, miR-650, and let-7b, and validated their role by 
examining 104 tissue samples (validation cohort). Con-
tinual efforts have been made to establish a miR panel to 
improve the detection of early relapse in CRC patients 
postoperatively and subsequently to augment therapeutic 
strategies and clinical outcomes.
Methods
Patients and tumor samples
In this study, we recruited 104 patients with primary 
CRC stages II–III according to the Union for Interna-
tional Cancer Control (UICC) classification (54 non-
early relapsed and 50 early relapsed patients after radical 
resection) from one institution. All 104 CRC patients 
who were included into the current study did not receive 
pre-operative neoadjuvant radiochemotherapy. The defi-
nition of radical resection is defined as surgical resection 
that takes the blood supply and lymph system supplying 
the organ along with the organ. Postoperative relapse was 
defined as the occurrence of postoperative local recur-
rent metastasis (tumor growth restricted to the anasto-
mosis or the region of the primary surgery) or distant 
metastasis (distant organ metastasis or diffuse perito-
neal seeding). Early relapse was defined as postoperative 
relapse occurring within 1 year after radical resection [5, 
11, 26, 27]. No-nearly relapse was defined as postopera-
tive relapse occurring 1 year after radical resection or no 
relapse until the last follow-up visit. All patients were 
unrelated ethnic Chinese residing in Taiwan. To deter-
mine miRs predicting early relapse, tissues were rapidly 
frozen in liquid nitrogen after resection. Clinical samples 
were obtained with informed consent from all patients, 
and the study protocol was approved by the Kaohsiung 
Medical University Hospital Institutional Review Board. 
All patients were followed up until their death or Decem-
ber 2013. The median follow-up time was 29  months 
(range 5–65  months). Disease-free survival (DFS) was 
defined as the time between resection and CRC relapse 
or the last follow-up visit. Overall survival (OS) was 
defined as the elapsed time between resection and death 
from any cause or the last follow-up visit.
RNA extraction and cDNA preparation
Approximately 100  mg of each tissue sample was 
homogenized using a bench-top homogeniser (Polytron 
PT1600E; Kinematica AG, Lucerne, Switzerland) in 1 mL 
of TRIzol reagent (Invitrogen, Carlsbad, CA, USA) for 
total RNA extraction according to the manufacturer’s 
instructions. For the miR array, the synthesis of cDNA for 
the miRs was performed using Megaplex Reverse Tran-
scription Human Pool A and Pool B (Applied Biosystems, 
Inc., CA, USA). For individual miR assays, the cDNA of 
each miR was synthesized with a unique primer (Applied 
Biosystems, Inc.) by using 20  ng of total RNA. For the 
mRNA quantitative assay, cDNAs were synthesized from 
1  μg of total RNA with random hexamers primers by 
using Reverse Transcriptase (Applied Biosystems, Inc.).
miR array
The miR array was performed as described in our previ-
ous study [27]. In summary, tissue samples from three 
primary CRC patients (one non-early relapsed and two 
early relapsed patients) were screened using a miR array 
(Applied Biosystems, Inc.) containing 667 human miRs 
and mammalian U6b as the internal control to identify 
differentially expressed miRs between early and nonearly 
relapsed CRC patients. A real-time quantitative poly-
merase chain reaction (RT-qPCR) was performed in the 
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Applied Biosystems 7900HT Real-Time PCR System by 
using the default thermal cycling conditions of the ABI 
7900 Sequence Detection System, Version 2.4 [28].
Assay for each miR
The TaqMan miR RT-qPCR assay (Applied Biosys-
tems, Inc.) was used to quantify the expression level of 
each candidate miR. The relative expression level of the 
miR was normalized to that of the internal control U6b 
by using the following equation: log10 (2−ΔCt), where 
ΔCt =  (CtmiR−CtU6b). The mean and standard deviation 
(SD) values of log10 (2−ΔCt) were calculated.
Statistical analyses
The continuous variables are represented as mean ± SD, 
and the dichotomous variables are represented as num-
ber and percentage values. Analysis of covariance were 
performed using JMP Version 10.0 software (SAS Insti-
tute, Inc., Cary, NC, USA) and used to compare the mean 
levels of miR expression between early and nonearly 
relapsed patients, with other clinicopathologic char-
acteristics as covariates. DFS and OS were calculated 
using the Kaplan–Meier method, and differences in sur-
vival rates were determined using the log-rank test. The 
linear regression and correlation of the miR RT-qPCR 
were analyzed. Receiver-operating characteristic (ROC) 
curves were constructed, with area under the ROC 
curves (AUC) and corresponding 95 % confidence inter-
vals (CIs) being calculated for each miR. The cut-off value 
with the highest accuracy (minimal false-negative and 
false-positive results) was determined. A 2-tailed P value 
less than 0.05 was considered statistically significant.
Results
Demographic data
The characteristics of 104 CRC patients (54 non-early 
relapsed and 50 early relapsed patients) are summa-
rized in Table  1. Their mean age was 69.5  years (range 
24–88 years). The status of early relapse is also shown in 
Table 1. Early relapsed patients had more advanced UICC 
stages than did non-early relapsed patients (P  =  0.019, 
Table  1); however, no significant differences were 
observed in other parameters including age, sex, tumor 
depth, or tumor size (all P > 0.05). Significant differences 
were observed in the tumor location (P = 0.0001) and the 
presence of vascular invasion (P = 0.003), perineural inva-
sion (P = 0.007), and lymph node metastasis (P = 0.019) 
between the non-early relapsed and early relapsed groups.
miR array and follow‑up validation
Three primary CRC patients (one nonearly relapsed and 
two early relapsed patients) were screened using the miR 
array (Applied Biosystems, Inc.) to identify differentially 
expressed miRs between early and nonearly relapsed 
CRC patients (data not shown). We initially used an arbi-
trary cutoff point of a 2.5-fold change to select 52 poten-
tial candidate miRs. Some of them have been reported to 
be related to colorectal cancers, and their potential target 
genes also have been checked in silico analysis. We identi-
fied 10 miR candidates, miR-7, miR-31, miR-93, miR-141, 
Table 1 Clinicopathologic characteristics of  104 patients with  UICC stage II–III colorectal cancer (comprising non-early 
relapsed and early relapsed patients)
UICC Union for international cancer control, A adenocarcinoma, M mucinous carcinoma, WD well differentiated, MD moderately well differentiated, PD poorly 
differentiated








Age (<65/≥65 year) 19/35 23/27 0.261
Gender (F/M) 20/34 20/30 0.756
UICCa stage (II/III) 34/20 20/30 0.019
Depth of invasion (T1/T2/T3/T4) 0/2/45/7 0/1/43/6 0.857
Maximum size (<5/≥5 cm) 28/26 25/25 0.850
Location (colon/rectum) 48/6 28/22 0.0001
Vascular invasion (N/Y) 46/8 30/20 0.003
Perineural invasion (N/Y) 46/8 31/19 0.007
Lymph node metastasis [N(−)/N(+)] 34/20 20/30 0.019
Type of tumor (A/M) 52/2 42/8 0.029
Histology (WD/MD/PD) 1/45/8 0/44/6 0.465
Mean ± SD Mean ± SD P value
Age 66.50 ± 12.05 65.10 ± 14.43 0.594
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miR-195, miR-375, miR-429, miR-494, miR-650, and let-
7b, and further validated their expression levels between 
the early and non-early relapsed CRC patients. To confirm 
the expression levels of the 10 candidates, we examined 
104 additional CRC samples: 54 from non-early relapsed 
patients and 50 from early relapsed patients. Six miRs, 
miR-195, let-7b, miR-7, miR-93, miR-141, and miR-494, 
were validated as being associated with early relapse. The 
expression levels of let-7b, miR-93, and miR-195 were sig-
nificantly lower in samples from the early relapsed patients 
(by 0.367-, 0.286-, and 0.608-fold, respectively) than in 
those from the nonearly relapsed patients (Table 2; Fig. 1). 
The expression levels of miR-7, miR-141, and miR-494 were 
considerably higher in samples from the early relapsed 
patients (by 2.24-, 2.88-, and 3.72-fold, respectively) than in 
those from the nonearly relapsed patients (Table 2; Fig. 1). 
Analysis of the correlations of deregulated miRs with 
clinical characteristics revealed the association of different 
miR expression levels with different variables, in addition to 
a significant correlation with early relapse (Table 3). A high 
expression level of miR-7 was associated with the pres-
ence of perineural invasion (P =  0.006). Advanced UICC 
stage (P = 0.029) was associated with a low miR-93 expres-
sion level (Table  3). Similarly, an advanced UICC stage 
(P = 0.032) was associated with a high miR-494 expression 
level (Table  3). In addition, a high expression level of let-
7b was observed in younger patients (P = 0.005). Among 
6 miRs, the expression level of miR-141 and miR-494 were 
associated with the tumor location (P < 0.05, Table 3).
DFS and OS analysis
The CRC patients were divided into subgroups according 
to the cut-off values in the ROC curve of the miR expres-
sion levels: high and low expression subgroups for the 
corresponding miRs. The DFS and OS of the 104 CRC 
patients in the two expression subgroups were assessed 
using the Kaplan–Meier method (Figs.  2, 3). Patients 
with low expression levels of miR-93 and miR-195 had 
significantly worse DFS (Fig.  2b, d) and OS (Fig.  3b, 
d). The patients in the high miR-7, miR-141, and miR-
494 expression subgroups had significantly worse DFS 
(Fig. 2a, c, e) and OS (Fig. 3a, c, e) than did those in the 
low miR-7, miR-141, and miR-494 expression subgroups.
ROC curve analysis
The sensitivity and specificity of the 6 miRs of the CRC 
patients are listed in Table 4. The diagnostic accuracy of 
each miR ranged from 56.3 to 73.1  %. ROC curves for 
each of the six candidate miRs were constructed using 
data from the 104 individuals evaluated (Fig. 4a). A panel 
of 6 miRs, with a cut-off value of 2 deregulated miRs, dis-
tinguished early relapsed CRC patients from non-early 
relapsed CRC patients, with an accuracy of 77.4 % (AUC 
0.834, 95 % CI = 0.740–0.905); a sensitivity of 76.6 % and 
a specificity of 71.4 % were obtained (Table 4; Fig. 4b). In 
Table  1, six clinicopathologic factors (UICC stage, loca-
tion, type of tumor, vascular invasion, perineural inva-
sion and lymph node metastasis) correlated with relapse 
status; therefore, we combined 6-miRs panel with these 
6 clinicopathologic factors to increase the predictive 
value (AUC 0.948, 95 % CI 0.881–0.984); a sensitivity of 
89.4 %, a specificity of 88.9 % and a accuracy of 89.1 were 
obtained were obtained (Table 4; Fig. 4c).
Discussion
In the present study, data showed that early relapse was 
significantly associated with CRC stages that were more 
advanced, tumor location, and the presence of vascular 
invasion, perineural invasion, and lymph node metasta-
sis. Initially, we used miR profiling to identify 10 miRs 
as potential biomarkers for the detection of early CRC 
relapse. In the validation study, additional samples from 
CRC patients were analyzed, and we confirmed that early 
relapse was significantly associated with decreased miR-
93, miR-195, and let-7b expression levels and increased 
miR-7, miR-141, and miR-494 expression levels.
Several previous studies have indicated that miR-93, 
miR-195, and members of the let-7 family of miRs are 
downregulated in lung cancer, CRC, and melanoma 
tissues as compared with normal tissue, suggesting 
that these miRs are tumor suppressors [29–37]. miR-
93 can suppress the proliferation of human colon can-
cer cells and colon cancer stem cells, with worse OS 
being associated with low miR-93 expression in CRC 
patients [37, 38]. miR-195 can suppress tumor cell pro-
liferation and metastasis by targeting several proteins, 
including BCOX1, BCL-2, and CARMA3 [32–34]. 
The overexpression of let-7b in  vitro can downregulate 
cell-cycle-related proteins, including cyclin D1, cyclin 
Table 2 Expression levels of  10 microRNAs in  non-early 
relapsed and early relapsed colorectal cancer patients
miR Non‑early relapsed 
(N = 54) mean ± SD
Early relapsed  
(N = 50) mean ± SD
P value
miR‑7 −0.843 ± 0.673 −0.493 ± 0.723 0.014
miR‑31 −0.054 ± 0.863 0.192 ± 0.816 0.138
miR‑93 1.902 ± 0.639 1.359 ± 0.527 <.0001
miR‑141 −0.028 ± 0.631 0.432 ± 0.705 0.001
miR‑195 0.465 ± 0.561 0.249 ± 0.490 0.040
miR‑375 1.781 ± 0.782 1.768 ± 0.781 0.933
miR‑429 0.388 ± 0.784 0.335 ± 0.588 0.696
miR‑494 1.771 ± 1.093 2.342 ± 1.243 0.016
miR‑650 1.358 ± 0.696 1.249 ± 0.766 0.454
let‑7b 2.573 ± 0.691 2.138 ± 0.607 0.002
Page 5 of 12Yang et al. J Transl Med  (2016) 14:108 
D3, cyclin-dependent kinase 4, and the high-mobility 
group protein and oncogene [30, 39]. Tzatsos and Bar-
deesy found that increased let-7b expression can con-
tribute to a decline in the formation of neurons and the 
self-renewal potential of neural stem cells during aging 
[39]. Although let-7b upregulation is observed in aged 
neural stem cells and is associated with the severity of 
lens opacity during aging [40], we discovered that down-
regulation of let-7b is an early relapse biomarker, par-
ticularly in elderly patients. miR-141 has been reported 
to inhibit the migration and proliferation of gastric 
cancer cells [40, 41], whereas other studies have shown 
Fig. 1 Expression levels of deregulated miR‑7, miR‑93, miR‑141, miR‑195, miR‑494, and let‑7b in human CRC tumors. The relative expression level 
of miR is represented by log10 (2
−ΔCt); ΔCt = (CtmiR−CtU6b), with U6b as the internal control for normalization. a The samples from early relapsed 
patients showed significantly increased miR‑7 expression levels (P = 0.014). b The samples from early relapsed patients showed significantly 
decreased miR‑93 expression levels (P < 0.0001). c The samples from early relapsed patients showed significantly increased miR‑141 expression 
levels (P = 0.001). d The samples from early relapsed patients showed significantly decreased miR‑195 expression levels (P = 0.040). e The samples 
from early relapse patients showed significantly decreased miR‑494 expression levels (P = 0.016). f The samples from early relapsed patients showed 
significantly decreased let‑7b expression levels (P = 0.002)
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that miR-141 has oncogenic characteristics in CRC and 
prostate cancer [42, 43]. Yin et  al. identified miR-141 
as a potential circulating biomarker for metastasis [44], 
consistent with our findings of high miR-141 expression 
in early relapsed CRC patients. Previous studies have 
shown that miR-7 functions as a tumor suppresser in 
CRC by targeting oncogenic YY1 and XRCC2 [45–47]. 
By contrast, we found that the upregulation of miR-7 
was more frequent in early relapsed CRC patients. Some 
studies have demonstrated miR-494 as tumor suppres-
sors in CRC [48–51]; however, in this study, miR-494 
expression levels showed a more significant increase 
in the samples from the early relapsed patients than in 
those from the non-early relapsed patients. Regarding 
the clinical outcomes, DFS and OS were significantly 
worse in the high miR-7, miR-141, and miR-494 expres-
sion subgroups and the low miR-93 and miR-195 expres-
sion subgroups.
Fig. 2 Disease‑free survival rates of 104 colorectal cancer (CRC) patients. Disease‑free survival rates were assessed using the Kaplan–Meier method, 
and differences in survival rates were determined using the log‑rank test. CRC patients were divided into low and high expression subgroups based 
on the cut‑off value in the ROC curve of miR expression. a–f Disease‑free survival was significantly shorter in CRC patients in the high miR‑7 (a, 
P = 0.033), miR‑141 (c, P < 0.0001), and miR‑494 (e, P = 0.03) expression subgroups. Disease‑free survival was significantly longer in CRC patients in 
the high miR‑93 (b, P < 0.0001), miR‑195 (c, P = 0.002), and let‑7b (e, P = 0.015) expression subgroups
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There are significant differences in UICC stage, loca-
tion, type of tumor, vascular invasion, perineural inva-
sion and lymph node metastasis between the non-early 
relapsed and early relapsed group, these may due to the 
gene expression profile or miR expression profile differ-
ence or tumors with different clinicopathologic charac-
teristics [8, 9, 52–56]. To date, carcinoembryonic antigen 
(CEA) is the recommended tumor marker for the postop-
erative surveillance of CRC recurrence in clinical practice. 
However, in a quantitative meta-analysis of 20 studies 
(4285 patients), Tan et al. found that the overall sensitiv-
ity and specificity of CEA for detecting CRC relapse were 
63.9 % (95 % CI 0.613–0.665) and 90.4 % (95 % CI 0.892–
0.914), respectively [57]. They concluded that serum CEA 
is a marker with a high specificity but insufficient sensi-
tivity for detecting CRC recurrence [57]. Su et  al. inves-
tigated 413 patients and found that the sensitivity of 
CEA for detecting CRC relapse was 54.4 % and that the 
sensitivities of CEA for detecting local recurrence, single 
metastasis, and multiple metastases were 36.6, 66.7, and 
Fig. 3 Cumulative survival rates of 104 patients with UICC stage II–III CRC. The overall survival of the CRC patients was assessed using the Kaplan–
Meier method, and differences in the survival rates were determined using the log‑rank test. Based on the ROC curve of the miR expression level, 
CRC patients were divided into low and high expression subgroups. (a–e) Overall survival was significantly worse in CRC patients in the low miR‑7 
(a, P = 0.021), miR‑141 (c, P = 0.004), and miR‑494 (e, P = 0.013) expression subgroups and the high miR93 (b, P = 0.030) and miR‑195 (d, P = 0.047) 
expression subgroups. f No significant differences were observed in let‑7B between the high and low expression subgroups (P = 0.123)
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Table 4 Sensitivity and specificity of the 6 candidate microRNAs of 104 patients with UICC stage II–III colorectal cancer 
according to real-time quantitative PCR
a Area under the ROC curve
b The optimal cut-off value for each microRNA was calculated by analyzing receiver-operating characteristic (ROC) curves, with the relative expression level of miR 
being normalized to U6b
c Accuracy is defined as the proportion of samples correctly classified into early relapsed (true positives) or nonearly relapsed (true negatives) groups
microRNAs AUCa (95 % CI) Cut‑offb  
value
Sensitivity (%) Specificity (%) Accuracyc (%)
miR‑7 0.647 (0.543–0.739) −0.37 53.1 80.0 66.7
miR‑93 0.752 (0.658–0.832) 1.57 72.0 74.1 73.1
miR‑141 0.617 (0.516–0.711) 0.59 76.9 52.6 72.8
miR‑195 0.615 (0.514–0.710) 0.93 96.0 26.4 56.3
miR‑494 0.634 (0.534–0.727) 3.05 42.9 85.2 61.2
let‑7b 0.671 (0.567–0.764) 2.09 55.1 76.1 61.1
6‑miR panel 0.834 (0.740–0.905) 2.00 76.6 71.4 77.4
Combined panel 0.948 (0.881–0.984) 4.00 89.4 88.9 89.1
Page 10 of 12Yang et al. J Transl Med  (2016) 14:108 
75.0  %, respectively [58]. Although it is frequently used 
for tumor surveillance, the sensitivity of CEA for detect-
ing CRC relapse is not optimal. miRs can be useful bio-
markers for detecting CRC relapse. Kanaan et al. and Luo 
et  al. also developed plasma miR panels that specifically 
distinguished CRC patients from healthy controls [59, 
60]. By combining the signature of 6-miRs (miR-7, mi-93, 
miR-141, miR-195, miR-494, and let-7b) with clinico-
pathologic characteristics, we successfully detected early 
relapsed CRC patients with a better accuracy [61]. The 
sensitivity and specificity of our combine panel for detect-
ing early relapse in CRC patients were improved to be 
89.4 and 88.9 %, respectively. The role of the 6-miRs com-
bine panel in the auxiliary role of CEA in the detection of 
early relapse of post-operative CRC patients might be cru-
cial in the clinical implications. However, a prospective, 
large-scale study is required to demonstrate the clinical 
role of this 6-miRs combine panel in the detection of early 
relapsed CRC patients following radical resection.
Conclusion
This study is the first to demonstrate that a 6-miR-based 
biomarker signature consisting of both up- and down-
regulated miRs could identify early CRC relapse post-
operatively. More prognostic studies should further 
investigate the association between the dysregulation of 
these 6 miRs and early relapse to identify CRC patients at 
a high risk of early relapse after radical resection.
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